Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and
up to 30% do not respond at all. Genetic factors contribute for about 50% of the AD …

The ATP-binding cassette family of transporter proteins, subfamily B (MDR/TAP), member 1
(ABCB1)(P-glycoprotein) transporter is a key component of the blood–brain barrier. Many …

Large differences in clinical response to selective serotonin reuptake inhibitors (SSRIs) are
observed in depressive patients with different genotypes. Quantification of these differences …

Major Depression Disorder (MDD) is a serious mental illness that is one of the most
disabling diseases worldwide. In addition, approximately 15% of depression patients are …

BackgroundThere have been conflicting reports on whether the length polymorphism in the
promoter of the serotonin transporter gene (5-HTTLPR) moderates the antidepressant …

Emergence of suicidal ideation (TESI) during treatment with antidepressants in major
depression led to a black box warning. We performed a genome-wide association study to …

Pharmacogenetic studies in mood disorders are raising increasing interest, after the first
findings of a significant association between antidepressant response and a functional …

OBJECTIVE: The authors sought to identify genetic markers for antidepressant medication
intolerance. Genetic variation in drug metabolizing enzymes such as cytochrome P450 2D6 …

Background and aims Treatment‐resistant depression (TRD), defined as inadequate
treatment response after at least two adequate treatment trials, is common among patients …

BACKGROUND: The study objective was to evaluate variations in genes implicated in
antidepressant mechanism of action for association with response to duloxetine treatment in …